Retatrutide’s Phase 3 diabetes data published in The Lancet and presented at ADA 2026
Retatrutide’s first Phase 3 type 2 diabetes trial, TRANSCEND-T2D-1, was published in The Lancet and presented with TRIUMPH-1 obesity data at ADA 2026.
-
-
New analytical method improves de novo sequencing of short peptides
Researchers at Kyushu University report a coumarin-tag method in Analytical Chemistry that improves accurate de novo sequencing of short peptides by mass spectrometry.
-
How Much BAC Water for a Target Concentration: The Reconstitution Math
How much BAC water for a target concentration? It is one division: water volume = vial amount divided by desired mg/mL. Worked examples, syringe math, and pitfalls.
-
Common Peptide Reconstitution Mistakes (and How to Avoid Them)
The six most common peptide reconstitution mistakes — shaking, wrong diluent, jetting onto the powder, bad math, contamination, and storage slips — and how to avoid each.
-
What DAC Means on a Peptide: Drug Affinity Complex Explained
DAC (Drug Affinity Complex) lets a peptide bind your own albumin to last days instead of minutes, with CJC-1295 as the classic example.
-
Freeze-Thaw Cycles and Aliquoting Peptides
Why repeated freeze-thaw degrades peptides and how aliquoting limits the damage.
-
U-100 vs U-40 Syringes: Why the Scale Matters
The two insulin-syringe scales, the 2.5x misread risk, and how to tell them apart.
-
Vial Labeling Best Practices
What to record on a reconstituted vial, and how to make labels that last.
-
Storing Lyophilized vs Reconstituted Peptides
Why dry and dissolved peptides need different storage, and how to handle each.
-
Endotoxin testing and LAL: why peptide purity isn’t the whole story
When people evaluate a research peptide’s quality, the first number they look at is usually the HPLC purity percentage. But purity is only one of the questions a good Certificate of Analysis answers — and on its own it can be misleading. Here is why endotoxin testing matters just as much. Purity answers one question…